Clinical evaluation of a new sulfonylurea in maturity onset diabetes - glipizide (K-4024).
Glipizide, a new low dose sulfonylurea, was evaluated for its efficacy and toxicity in a double-blind controlled study. Forty adult-onset diabetics were treated with either chlorpropamide or glipizide. In ten out of twenty patients "excellent" to "good" control of hyperglycemia was achieved with glipizide and two patients evidenced "fair" control. In nine out of eighteen patients "excellent" to "good" control was achieved with chlorpropamide. Eight of the sixteen patients who were primary or secondary failures on the two drugs responded to glipizide and phenformin combination with "excellent" to "good" control. No therapeutic advantage was found in giving more than 25 mg/day glipizide in ten patients. Toxicity was low and side effects were uncommon over a period of 26 months.
D000328:Adult; D000368:Aged; D002747:Chlorpropamide / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005913:Glipizide / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D010629:Phenformin / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D014044:Tolbutamide / Q000627:therapeutic use
D013453:Sulfonylurea Compounds; D014044:Tolbutamide; D010629:Phenformin; D002747:Chlorpropamide; D005913:Glipizide